KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

West Pharmaceutical Services (WST) Receivables (2016 - 2025)

West Pharmaceutical Services' Receivables history spans 17 years, with the latest figure at $586.3 million for Q4 2025.

  • For Q4 2025, Receivables rose 1.82% year-over-year to $586.3 million; the TTM value through Dec 2025 reached $586.3 million, up 1.82%, while the annual FY2025 figure was $586.3 million, 1.82% up from the prior year.
  • Receivables for Q4 2025 was $586.3 million at West Pharmaceutical Services, down from $652.5 million in the prior quarter.
  • Across five years, Receivables topped out at $652.5 million in Q3 2025 and bottomed at $478.2 million in Q1 2021.
  • The 5-year median for Receivables is $536.2 million (2023), against an average of $540.7 million.
  • The largest annual shift saw Receivables skyrocketed 37.27% in 2021 before it fell 9.68% in 2024.
  • A 5-year view of Receivables shows it stood at $503.6 million in 2021, then grew by 3.99% to $523.7 million in 2022, then grew by 1.87% to $533.5 million in 2023, then rose by 7.93% to $575.8 million in 2024, then increased by 1.82% to $586.3 million in 2025.
  • Per Business Quant, the three most recent readings for WST's Receivables are $586.3 million (Q4 2025), $652.5 million (Q3 2025), and $610.3 million (Q2 2025).